{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:15:56Z","timestamp":1782828956733,"version":"3.54.5"},"reference-count":65,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0641-x","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T13:02:38Z","timestamp":1563368558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer"],"prefix":"10.1136","volume":"7","author":[{"given":"A. J. Robert","family":"McGray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruea-Yea","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Eppolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Miliotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle B.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit A.","family":"Lugade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Lichty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukund","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Kozbor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"issue":"1","key":"641_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"641_CR2","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374\u2013403.","journal-title":"Eur J Cancer"},{"issue":"5","key":"641_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/ijc.27711","volume":"132","author":"F Bray","year":"2013","unstructured":"Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133\u201345.","journal-title":"Int J Cancer"},{"issue":"9","key":"641_CR4","doi-asserted-by":"crossref","first-page":"15621","DOI":"10.18632\/oncotarget.14919","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget. 2017;8(9):15621\u201331.","journal-title":"Oncotarget."},{"issue":"51","key":"641_CR5","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"641_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313.","journal-title":"N Engl J Med"},{"issue":"2","key":"641_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/biomedicines4020010","volume":"4","author":"Silvia Martin Lluesma","year":"2016","unstructured":"Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE. Cancer vaccines in ovarian Cancer: how can we improve? Biomedicines. 2016;4(2).","journal-title":"Biomedicines"},{"issue":"1","key":"641_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","volume":"2","author":"K Odunsi","year":"2014","unstructured":"Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014;2(1):37\u201349.","journal-title":"Cancer Immunol Res."},{"issue":"15","key":"641_CR9","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1073\/pnas.1117208109","volume":"109","author":"K Odunsi","year":"2012","unstructured":"Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012;109(15):5797\u2013802.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15_suppl","key":"641_CR10","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","volume":"34","author":"ML Disis","year":"2016","unstructured":"Disis ML, Patel MR, Pant S, Hamilton EP, Lockhart AC, Kelly K, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity. J Clin Oncol. 2016;34(15_suppl):5533.","journal-title":"J Clin Oncol"},{"issue":"34","key":"641_CR11","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian Cancer. J Clin Oncol. 2015;33(34):4015\u201322.","journal-title":"J Clin Oncol"},{"issue":"7457","key":"641_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u20138.","journal-title":"Nature."},{"issue":"9","key":"641_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how Cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"issue":"4","key":"641_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to Cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell."},{"key":"641_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116\u201329.","journal-title":"Eur J Cancer"},{"issue":"11","key":"641_CR16","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","volume":"14","author":"M Nishino","year":"2017","unstructured":"Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655\u201368.","journal-title":"Nat Rev Clin Oncol"},{"issue":"29","key":"641_CR17","doi-asserted-by":"crossref","first-page":"27359","DOI":"10.18632\/oncotarget.4751","volume":"6","author":"RY Huang","year":"2015","unstructured":"Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6(29):27359\u201377.","journal-title":"Oncotarget."},{"issue":"8","key":"641_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559\u201367.","journal-title":"Nat Rev Cancer"},{"key":"641_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fonc.2017.00114","volume":"7","author":"DE Meyers","year":"2017","unstructured":"Meyers DE, Wang AA, Thirukkumaran CM, Morris DG. Current immunotherapeutic strategies to enhance oncolytic Virotherapy. Front Oncol. 2017;7:114.","journal-title":"Front Oncol"},{"issue":"6","key":"641_CR20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic Virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109\u201319 e10.","journal-title":"Cell."},{"issue":"3","key":"641_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ygyno.2017.07.135","volume":"146","author":"DE Cohn","year":"2017","unstructured":"Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, et al. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin(R)) in recurrent ovarian, tubal, or peritoneal cancer: an NRG oncology\/gynecologic oncology group study. Gynecol Oncol. 2017;146(3):477\u201383.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"641_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","volume":"70","author":"E Galanis","year":"2010","unstructured":"Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010;70(3):875\u201382.","journal-title":"Cancer Res"},{"issue":"1","key":"641_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","volume":"75","author":"E Galanis","year":"2015","unstructured":"Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res. 2015;75(1):22\u201330.","journal-title":"Cancer Res"},{"issue":"8","key":"641_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2010.103","volume":"18","author":"J Brun","year":"2010","unstructured":"Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, et al. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther. 2010;18(8):1440\u20139.","journal-title":"Mol Ther"},{"key":"641_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/OV.S154494","volume":"7","author":"JG Pol","year":"2018","unstructured":"Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, et al. Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virother. 2018;7:117\u201328.","journal-title":"Oncolytic Virother"},{"issue":"31","key":"641_CR26","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","volume":"33","author":"VL Chiou","year":"2015","unstructured":"Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541\u20133.","journal-title":"J Clin Oncol"},{"issue":"23","key":"641_CR27","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"641_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/carcin\/21.4.585","volume":"21","author":"KF Roby","year":"2000","unstructured":"Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21(4):585\u201391.","journal-title":"Carcinogenesis."},{"issue":"3","key":"641_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.vaccine.2010.10.040","volume":"29","author":"RC Girvan","year":"2011","unstructured":"Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA. MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Vaccine. 2011;29(3):545\u201357.","journal-title":"Vaccine."},{"issue":"2","key":"641_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/mt.2013.249","volume":"22","author":"JG Pol","year":"2014","unstructured":"Pol JG, Zhang L, Bridle BW, Stephenson KB, Resseguier J, Hanson S, et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther. 2014;22(2):420\u20139.","journal-title":"Mol Ther"},{"key":"641_CR31","unstructured":"Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014."},{"issue":"7","key":"641_CR32","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"269","key":"641_CR33","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Sci Signal"},{"issue":"17","key":"641_CR34","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1093\/bioinformatics\/btr406","volume":"27","author":"U Bodenhofer","year":"2011","unstructured":"Bodenhofer U, Kothmeier A, Hochreiter S. APCluster: an R package for affinity propagation clustering. Bioinformatics. 2011;27(17):2463\u20134.","journal-title":"Bioinformatics."},{"key":"641_CR35","volume-title":"Modeling survival data: extending the cox model","author":"TM Therneau","year":"2013","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York: Springer-Verlag; 2013."},{"key":"641_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2015.13","volume":"2","author":"JG Tong","year":"2015","unstructured":"Tong JG, Valdes YR, Barrett JW, Bell JC, Stojdl D, McFadden G, et al. Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis. Mol Ther Oncolytics. 2015;2:15013.","journal-title":"Mol Ther Oncolytics"},{"issue":"7655","key":"641_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nature22367","volume":"545","author":"M Philip","year":"2017","unstructured":"Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545(7655):452\u20136.","journal-title":"Nature."},{"issue":"5","key":"641_CR38","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1172\/JCI99538","volume":"129","author":"Fangjun Chen","year":"2019","unstructured":"Chen F, Zou Z, Du J, Su S, Shao J, Meng F, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest. 2019;130. https:\/\/doi.org\/10.1172\/JCI99538 .","journal-title":"Journal of Clinical Investigation"},{"key":"641_CR39","doi-asserted-by":"publisher","unstructured":"Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, et al. A phase 1 dose escalation trial of BN-CV301, a recombinant Poxviral vaccine targeting MUC1 and CEA with costimulatory molecules. Clin Cancer Res. 2019. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0183 . Epub ahead of print.","DOI":"10.1158\/1078-0432.CCR-19-0183"},{"issue":"7738","key":"641_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240\u20135.","journal-title":"Nature."},{"key":"641_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7.","journal-title":"NPJ Vaccines"},{"issue":"7","key":"641_CR42","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00262-019-02331-x","volume":"68","author":"Amit Mahipal","year":"2019","unstructured":"Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, et al. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunol Immunother. 2019;68(7):1211-22. https:\/\/doi.org\/10.1007\/s00262-019-02331-x . Epub 2019 May 8.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"12","key":"641_CR43","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/2326-6066.CIR-16-0156","volume":"4","author":"TM Johanns","year":"2016","unstructured":"Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, et al. Endogenous Neoantigen-specific CD8 T cells identified in two glioblastoma models using a Cancer Immunogenomics approach. Cancer Immunol Res. 2016;4(12):1007\u201315.","journal-title":"Cancer Immunol Res"},{"key":"641_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2017.09.017","volume":"120","author":"C Solinas","year":"2017","unstructured":"Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, et al. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol. 2017;120:13\u201321.","journal-title":"Crit Rev Oncol Hematol"},{"key":"641_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","volume":"88","author":"M Tazdait","year":"2018","unstructured":"Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38\u201347.","journal-title":"Eur J Cancer"},{"issue":"8","key":"641_CR46","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in Cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23(8):1920\u20138.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"641_CR47","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242\u201350.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"641_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):165.","journal-title":"Exp Mol Med"},{"issue":"2","key":"641_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","volume":"152","author":"A Varga","year":"2019","unstructured":"Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152(2):243\u201350.","journal-title":"Gynecol Oncol"},{"key":"641_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","volume":"3","author":"SL Gaillard","year":"2016","unstructured":"Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3:11.","journal-title":"Gynecol Oncol Res Pract"},{"key":"641_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754.","journal-title":"Nat Commun"},{"issue":"11","key":"641_CR52","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1172\/JCI125039","volume":"128","author":"D Zamarin","year":"2018","unstructured":"Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128(11):5184.","journal-title":"J Clin Invest"},{"issue":"22","key":"641_CR53","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene Laherparepvec in combination with Ipilimumab in previously untreated, Unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619\u201326.","journal-title":"J Clin Oncol"},{"issue":"1","key":"641_CR54","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-018-0337-7","volume":"6","author":"L Sun","year":"2018","unstructured":"Sun L, Funchain P, Song JM, Rayman P, Tannenbaum C, Ko J, et al. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. J Immunother Cancer. 2018;6(1):36.","journal-title":"J Immunother Cancer"},{"key":"641_CR55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","volume":"41","author":"JF Graaf de","year":"2018","unstructured":"de Graaf JF, de Vor L, Fouchier RAM, van den Hoogen BG. Armed oncolytic viruses: a kick-start for anti-tumor immunity. Cytokine Growth Factor Rev. 2018;41:28\u201339.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"641_CR56","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"CE Engeland","year":"2014","unstructured":"Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther. 2014;22(11):1949\u201359.","journal-title":"Mol Ther"},{"issue":"10","key":"641_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1220467","volume":"5","author":"P Kleinpeter","year":"2016","unstructured":"Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a fab and a scFv against programmed cell death \u22121 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology. 2016;5(10):e1220467.","journal-title":"Oncoimmunology."},{"issue":"3","key":"641_CR58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen landscape during immune checkpoint blockade in non-small cell lung Cancer. Cancer Discov. 2017;7(3):264\u201376.","journal-title":"Cancer Discov."},{"issue":"10","key":"641_CR59","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov."},{"issue":"8","key":"641_CR60","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","volume":"21","author":"AP Rapoport","year":"2015","unstructured":"Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914\u201321.","journal-title":"Nat Med"},{"issue":"1","key":"641_CR61","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","volume":"10","author":"Z Wang","year":"2017","unstructured":"Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10(1):53.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"641_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155189","volume":"11","author":"SD Martin","year":"2016","unstructured":"Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, et al. Low mutation burden in ovarian Cancer may limit the utility of Neoantigen-targeted vaccines. PLoS One. 2016;11(5):e0155189.","journal-title":"PLoS One"},{"issue":"10","key":"641_CR63","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.4049\/jimmunol.1400201","volume":"193","author":"M Gil","year":"2014","unstructured":"Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, et al. CXCL12\/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol. 2014;193(10):5327\u201337.","journal-title":"J Immunol"},{"issue":"8","key":"641_CR64","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/mt.2010.98","volume":"18","author":"BW Bridle","year":"2010","unstructured":"Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther. 2010;18(8):1430\u20139.","journal-title":"Mol Ther"},{"key":"641_CR65","doi-asserted-by":"publisher","unstructured":"Karandikar SH, Sidney J, Sette A, Selby MJ, Korman AJ, Srivastava PK. New epitopes in ovalbumin provide insights for cancer neoepitopes. JCI Insight. 2019;5. https:\/\/doi.org\/10.1172\/jci.insight.127882 .","DOI":"10.1172\/jci.insight.127882"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0641-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0641-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T02:25:59Z","timestamp":1610504759000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0641-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0641-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All performed animal experiments and procedures were reviewed and approved by the Roswell Park Comprehensive Cancer Center (RPCCC) IACUC. No human subjects were enrolled in any aspect of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KB Stephenson is an employee of Turnstone Biologics, who holds IP for Maraba Virus. G Webster is the Chief Scientific Officer of Innate Immunotherapeutics, who holds IP for MIS416. BD Lichty is an inventor, shareholder, and Chief Technology Officer of Turnstone Biologics, who holds IP for Maraba Virus. All other authors have no financial competing interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}